SCHEMBL6296539

SCHEMBL6296539

CC(C)(C)OC(=O)Nc1ccn(C(=O)OC(C)(C)C)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.39
DYRK1A Q13627 1/20 0.39
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CYP17A1 P05093 3/20 0.37
ATR Q13535 1/20 0.37
BRD9 Q9H8M2 1/20 0.37
BRD4 O60885 2/20 0.37
MAPT P10636 1/20 0.37
PCSK9 Q8NBP7 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36
MAPK14 Q16539 1/20 0.36
PTGER1 P34995 2/20 0.36
PSMB8 P28062 1/20 0.36
NAMPT P43490 1/20 0.36
ELOVL1 Q9BW60 1/20 0.35
SCN9A Q15858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27285314 0.85 ALDH1A1 (0.42) KDM4EALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL18675319 0.84 ELOVL1 (0.39) KDM4EALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL28138204 0.82 KDM4E (0.45) KDM4EALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL13472107 0.81 SMN1; SMN2 (0.54) GSK3BDYRK1AKDM4EALDH1A1LMNA
SCHEMBL10223048 0.81 PCSK9 (0.36) KDM4EALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL305276 0.81 PCSK9 (0.36) KDM4EALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL2662475 0.78 MAPT (0.40) MAPT
SCHEMBL25143558 0.78 PTGS1 (0.40) KDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL19937659 0.78 RAF1 (0.49) GSK3BDYRK1ACYP17A1ATRBRD9
SCHEMBL28055517 0.78 RAF1 (0.49) GSK3BDYRK1AALDH1A1SMN1; SMN2CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6977262-B2 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2005-12-20 US disclosed
CN-1630656-A Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORP (JP) 2005-06-22 CN disclosed
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-03-18 US disclosed
WO-2002062795-A9 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof GSK3B, GSK3A, PYGB GSK3B 1/4885DYRK1A 245/4885KDM4E 1992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.